Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 2,482 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal Failure Clear all
Completed Phase 2 Interventional Results available

A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease

NCT03270956
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions
Renal Autologous Cell Therapy (REACT)
Biological
Lead sponsor
Prokidney
Industry
Eligibility
30 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Tucson, Arizona • Boise, Idaho • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 22, 2026, 8:45 AM EDT
Completed Not applicable Interventional Results available

Drug-Targeted Alerts for Acute Kidney Injury

NCT02771977
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Drug-specific alert
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
5,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Oct 22, 2026, 8:45 AM EDT
Recruiting No phase listed Observational

Kidney Precision Medicine Project

NCT04334707
View directory record Official record
Conditions
Acute Kidney Failure, Acute Kidney Insufficiency, Acute Renal Failure, Acute Renal Injury, Acute Renal Insufficiency, Kidney Failure, Acute, Kidney Insufficiency, Acute, Renal Failure, Acute, Renal Insufficiency, Acute, Chronic Kidney Diseases, Chronic Kidney Insufficiency, Chronic Renal Diseases, Chronic Renal Insufficiency, Kidney Insufficiency, Chronic, Type 1 Diabetes (T1D)
Interventions
Kidney Biopsy, MRI, Retina Scan
Procedure · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
13
States / cities
Tucson, Arizona • New Haven, Connecticut • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 22, 2026, 8:45 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

NCT05457283
View directory record Official record
Conditions
Chronic Kidney Disease, Proteinuria, Children
Interventions
Finerenone (Kerendia, BAY94-8862)
Drug
Lead sponsor
Bayer
Industry
Eligibility
1 Year to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
18
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 22, 2026, 8:45 AM EDT
Completed No phase listed Observational

Endothelial Function and Arterio-Venous Fistula Maturation

NCT01604473
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 90 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2022 · Synced Oct 22, 2026, 8:45 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

NCT06004661
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions
AAA617, 68Ga-PSMA-11
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 22, 2026, 8:45 AM EDT
Completed Not applicable Interventional

Light Therapy in End Stage Kidney Disease

NCT06310161
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Bright light, Dim Light
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 8:45 AM EDT
Completed No phase listed Observational

Chitosan Chewing Gum Study in Dialysis Patients

NCT01770470
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Chitosan
Dietary Supplement
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 22, 2026, 8:45 AM EDT
Completed Not applicable Interventional

Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders

NCT01758042
View directory record Official record
Conditions
Chronic Kidney Disease, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL), Hodgkin Disease, Multiple Myeloma, Myelodysplastic Syndrome (MDS), Aplastic Anemia, AL Amyloidosis, Diamond Blackfan Anemia, Myelofibrosis, Myeloproliferative Disease, Sickle Cell Anemia, Autoimmune Diseases, Thalassemia
Interventions
Haploidentical Bone Marrow/Kidney
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 22, 2026, 8:45 AM EDT
Completed Not applicable Interventional

SOCIABLE Seniors Optimizing Community Integration to Advance Better Living With ESRD

NCT03055273
View directory record Official record
Conditions
ESRD, Social Behavior, Physical Disability
Interventions
SOCIABLE
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
60 Years to 100 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 22, 2026, 8:45 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Enhancing the Natriuretic Peptide System in HFpEF

NCT05279742
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Chronic Kidney Diseases
Interventions
MANP, Sacubitril/Valsartan, Oral Placebo, Injection Placebo
Drug
Lead sponsor
Horng Chen
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 22, 2026, 8:45 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Vasodilators and Anti-Oxidant Therapy in Early ATN

NCT00286403
View directory record Official record
Conditions
Acute Renal Failure
Interventions
Fenoldopam Mesylate and/or MESNA
Drug
Lead sponsor
Southeast Renal Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Oct 22, 2026, 8:45 AM EDT
Completed No phase listed Observational

Fluid Status of Dialysis Subjects

NCT07217041
View directory record Official record
Conditions
ESRD (End Stage Renal Disease)
Interventions
Not listed
Lead sponsor
HemoCept Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 22, 2026, 8:45 AM EDT
Completed Phase 4 Interventional Results available

Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus

NCT03774394
View directory record Official record
Conditions
Chronic Kidney Disease (CKD), Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease (CAD)
Interventions
Clopidogrel, Clopidogrel active metabolite
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 22, 2026, 8:45 AM EDT
Completed Not applicable Interventional Results available

Study to Determine the Efficacy of Real-time CGM in Preventing Hypoglycemia Among Insulin-treated Patients With DM2 on Hemodialysis, Compared to Standard of Care (POC BG)

NCT04473430
View directory record Official record
Conditions
End-Stage Renal Disease, Type 2 Diabetes
Interventions
Dexcom Real-time G6 Continuous Glucose Monitoring System (CGM), POC Glucose Testing
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 22, 2026, 8:45 AM EDT
Completed Not applicable Interventional

Pharmacokinetics, Pharmacodynamics and Safety of Basis in Acute Kidney Injury Study

NCT03176628
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Basis, Placebo
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 22, 2026, 8:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Single Ascending Dose Study of Soluble Ferric Pyrophosphate Administered Intravenously in Healthy Volunteers.

NCT01920854
View directory record Official record
Conditions
Kidney Failure, Chronic Therapy; Hemodialysis
Interventions
soluble ferric pyrophosphate, Placebo
Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 22, 2026, 8:45 AM EDT
Completed Phase 2 Interventional

Immune Effects of Vitamin D in Hemodialysis Patients

NCT00686751
View directory record Official record
Conditions
End Stage Renal Disease, Hemodialysis, Inflammatory Response, Cardiovascular Disease
Interventions
paricalcitol
Drug
Lead sponsor
Renal Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2009 · Synced Oct 22, 2026, 8:45 AM EDT
Completed No phase listed Observational

REVEAL-CKD: Prevalence and Consequences of Undiagnosed Chronic Kidney Disease

NCT04847531
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,006,361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Louisville, Kentucky • Cambridge, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 22, 2026, 8:45 AM EDT
Completed Not applicable Interventional

Decision Support for Detection of Chronic Kidney Disease in Type II Diabetes Mellitus

NCT05342545
View directory record Official record
Conditions
Chronic Kidney Diseases, Type2Diabetes
Interventions
Alert-based computerized decision support
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 22, 2026, 8:45 AM EDT
Recruiting No phase listed Observational

Improving Patient-Centered Care for Underserved Older African American Patients With Cardiovascular Comorbidities

NCT07748858
View directory record Official record
Conditions
Cardiovascular, Comorbidity, Diabetes, Inflammatory Joint Diseases, Chronic Kidney Diease, Chronic Obstructive Pulmonary Disease (COPD), Cardiovascular Disease
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 22, 2026, 8:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment

NCT07165015
View directory record Official record
Conditions
Renal Impairment, Healthy, Renal Insufficiency, End Stage Renal Disease (ESRD)
Interventions
LY3537031
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Orlando, Florida • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 22, 2026, 8:45 AM EDT
Completed Phase 2 Interventional

Kidney Transplant for HIV-Infected Patients in Renal Failure

NCT00009009
View directory record Official record
Conditions
Chronic Kidney Failure, HIV Infection
Interventions
immunosuppressive regimen designed to complement HAART
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 8:45 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis

NCT06609343
View directory record Official record
Conditions
End Stage Renal Disease, Fatigue
Interventions
Bupropion Hydrochloride 150 MG
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
25 Years to 74 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 22, 2026, 8:45 AM EDT